1 Hemophilia Drugs Market Overview 1.1 Product Overview and Scope of Hemophilia Drugs 1.2 Hemophilia Drugs Segment by Type 1.2.1 Global Hemophilia Drugs Sales Growth Rate Comparison by Type (2022-2028) 1.2.2 Hemophilia A 1.2.3 Inhibitors 1.2.4 Hemophilia B 1.2.5 Von Willebrand Disease 1.3 Hemophilia Drugs Segment by Application 1.3.1 Global Hemophilia Drugs Sales Comparison by Application: (2022-2028) 1.3.2 Recombinant Therapies 1.3.3 Plasma-Derived Therapies 1.4 Global Hemophilia Drugs Market Size Estimates and Forecasts 1.4.1 Global Hemophilia Drugs Revenue 2017-2028 1.4.2 Global Hemophilia Drugs Sales 2017-2028 1.4.3 Hemophilia Drugs Market Size by Region: 2017 Versus 2021 Versus 2028 2 Hemophilia Drugs Market Competition by Manufacturers 2.1 Global Hemophilia Drugs Sales Market Share by Manufacturers (2017-2022) 2.2 Global Hemophilia Drugs Revenue Market Share by Manufacturers (2017-2022) 2.3 Global Hemophilia Drugs Average Price by Manufacturers (2017-2022) 2.4 Manufacturers Hemophilia Drugs Manufacturing Sites, Area Served, Product Type 2.5 Hemophilia Drugs Market Competitive Situation and Trends 2.5.1 Hemophilia Drugs Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Hemophilia Drugs Players Market Share by Revenue 2.5.3 Global Hemophilia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Hemophilia Drugs Retrospective Market Scenario by Region 3.1 Global Hemophilia Drugs Retrospective Market Scenario in Sales by Region: 2017-2022 3.2 Global Hemophilia Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022 3.3 North America Hemophilia Drugs Market Facts & Figures by Country 3.3.1 North America Hemophilia Drugs Sales by Country 3.3.2 North America Hemophilia Drugs Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Hemophilia Drugs Market Facts & Figures by Country 3.4.1 Europe Hemophilia Drugs Sales by Country 3.4.2 Europe Hemophilia Drugs Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Hemophilia Drugs Market Facts & Figures by Region 3.5.1 Asia Pacific Hemophilia Drugs Sales by Region 3.5.2 Asia Pacific Hemophilia Drugs Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Hemophilia Drugs Market Facts & Figures by Country 3.6.1 Latin America Hemophilia Drugs Sales by Country 3.6.2 Latin America Hemophilia Drugs Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Hemophilia Drugs Market Facts & Figures by Country 3.7.1 Middle East and Africa Hemophilia Drugs Sales by Country 3.7.2 Middle East and Africa Hemophilia Drugs Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Hemophilia Drugs Historic Market Analysis by Type 4.1 Global Hemophilia Drugs Sales Market Share by Type (2017-2022) 4.2 Global Hemophilia Drugs Revenue Market Share by Type (2017-2022) 4.3 Global Hemophilia Drugs Price by Type (2017-2022) 5 Global Hemophilia Drugs Historic Market Analysis by Application 5.1 Global Hemophilia Drugs Sales Market Share by Application (2017-2022) 5.2 Global Hemophilia Drugs Revenue Market Share by Application (2017-2022) 5.3 Global Hemophilia Drugs Price by Application (2017-2022) 6 Key Companies Profiled 6.1 Baxalta 6.1.1 Baxalta Corporation Information 6.1.2 Baxalta Description and Business Overview 6.1.3 Baxalta Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.1.4 Baxalta Hemophilia Drugs Product Portfolio 6.1.5 Baxalta Recent Developments/Updates 6.2 Bayer 6.2.1 Bayer Corporation Information 6.2.2 Bayer Description and Business Overview 6.2.3 Bayer Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.2.4 Bayer Hemophilia Drugs Product Portfolio 6.2.5 Bayer Recent Developments/Updates 6.3 CSL Behring 6.3.1 CSL Behring Corporation Information 6.3.2 CSL Behring Description and Business Overview 6.3.3 CSL Behring Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.3.4 CSL Behring Hemophilia Drugs Product Portfolio 6.3.5 CSL Behring Recent Developments/Updates 6.4 Pfizer 6.4.1 Pfizer Corporation Information 6.4.2 Pfizer Description and Business Overview 6.4.3 Pfizer Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.4.4 Pfizer Hemophilia Drugs Product Portfolio 6.4.5 Pfizer Recent Developments/Updates 6.5 Alnylam Pharmaceuticals 6.5.1 Alnylam Pharmaceuticals Corporation Information 6.5.2 Alnylam Pharmaceuticals Description and Business Overview 6.5.3 Alnylam Pharmaceuticals Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.5.4 Alnylam Pharmaceuticals Hemophilia Drugs Product Portfolio 6.5.5 Alnylam Pharmaceuticals Recent Developments/Updates 6.6 BioMarin 6.6.1 BioMarin Corporation Information 6.6.2 BioMarin Description and Business Overview 6.6.3 BioMarin Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.6.4 BioMarin Hemophilia Drugs Product Portfolio 6.6.5 BioMarin Recent Developments/Updates 6.7 Catalyst Biosciences 6.6.1 Catalyst Biosciences Corporation Information 6.6.2 Catalyst Biosciences Description and Business Overview 6.6.3 Catalyst Biosciences Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.4.4 Catalyst Biosciences Hemophilia Drugs Product Portfolio 6.7.5 Catalyst Biosciences Recent Developments/Updates 6.8 Dimension Therapeutics 6.8.1 Dimension Therapeutics Corporation Information 6.8.2 Dimension Therapeutics Description and Business Overview 6.8.3 Dimension Therapeutics Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.8.4 Dimension Therapeutics Hemophilia Drugs Product Portfolio 6.8.5 Dimension Therapeutics Recent Developments/Updates 6.9 F. Hoffmann-La Roche 6.9.1 F. Hoffmann-La Roche Corporation Information 6.9.2 F. Hoffmann-La Roche Description and Business Overview 6.9.3 F. Hoffmann-La Roche Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.9.4 F. Hoffmann-La Roche Hemophilia Drugs Product Portfolio 6.9.5 F. Hoffmann-La Roche Recent Developments/Updates 6.10 Grifols 6.10.1 Grifols Corporation Information 6.10.2 Grifols Description and Business Overview 6.10.3 Grifols Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.10.4 Grifols Hemophilia Drugs Product Portfolio 6.10.5 Grifols Recent Developments/Updates 6.11 Octapharma 6.11.1 Octapharma Corporation Information 6.11.2 Octapharma Hemophilia Drugs Description and Business Overview 6.11.3 Octapharma Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.11.4 Octapharma Hemophilia Drugs Product Portfolio 6.11.5 Octapharma Recent Developments/Updates 6.12 Sangamo Biosciences 6.12.1 Sangamo Biosciences Corporation Information 6.12.2 Sangamo Biosciences Hemophilia Drugs Description and Business Overview 6.12.3 Sangamo Biosciences Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.12.4 Sangamo Biosciences Hemophilia Drugs Product Portfolio 6.12.5 Sangamo Biosciences Recent Developments/Updates 6.13 Spark Therapeutics 6.13.1 Spark Therapeutics Corporation Information 6.13.2 Spark Therapeutics Hemophilia Drugs Description and Business Overview 6.13.3 Spark Therapeutics Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.13.4 Spark Therapeutics Hemophilia Drugs Product Portfolio 6.13.5 Spark Therapeutics Recent Developments/Updates 6.14 Swedish Orphan Biovitrum 6.14.1 Swedish Orphan Biovitrum Corporation Information 6.14.2 Swedish Orphan Biovitrum Hemophilia Drugs Description and Business Overview 6.14.3 Swedish Orphan Biovitrum Hemophilia Drugs Sales, Revenue and Gross Margin (2017-2022) 6.14.4 Swedish Orphan Biovitrum Hemophilia Drugs Product Portfolio 6.14.5 Swedish Orphan Biovitrum Recent Developments/Updates 7 Hemophilia Drugs Manufacturing Cost Analysis 7.1 Hemophilia Drugs Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Hemophilia Drugs 7.4 Hemophilia Drugs Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Hemophilia Drugs Distributors List 8.3 Hemophilia Drugs Customers 9 Hemophilia Drugs Market Dynamics 9.1 Hemophilia Drugs Industry Trends 9.2 Hemophilia Drugs Market Drivers 9.3 Hemophilia Drugs Market Challenges 9.4 Hemophilia Drugs Market Restraints 10 Global Market Forecast 10.1 Hemophilia Drugs Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Hemophilia Drugs by Type (2023-2028) 10.1.2 Global Forecasted Revenue of Hemophilia Drugs by Type (2023-2028) 10.2 Hemophilia Drugs Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Hemophilia Drugs by Application (2023-2028) 10.2.2 Global Forecasted Revenue of Hemophilia Drugs by Application (2023-2028) 10.3 Hemophilia Drugs Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Hemophilia Drugs by Region (2023-2028) 10.3.2 Global Forecasted Revenue of Hemophilia Drugs by Region (2023-2028) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Hemophilia Drugs Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million) Table 2. Global Hemophilia Drugs Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million) Table 3. Global Hemophilia Drugs Market Size by Region (US$ Million) (2017 VS 2021 VS 2028) Table 4. Global Hemophilia Drugs Market Competitive Situation by Manufacturers in 2021 Table 5. Global Hemophilia Drugs Sales (K Units) of Key Manufacturers (2017-2022) Table 6. Global Hemophilia Drugs Sales Market Share by Manufacturers (2017-2022) Table 7. Global Hemophilia Drugs Revenue (US$ Million) by Manufacturers (2017-2022) Table 8. Global Hemophilia Drugs Revenue Share by Manufacturers (2017-2022) Table 9. Global Market Hemophilia Drugs Average Price (USD/Unit) of Key Manufacturers (2017-2022) Table 10. Manufacturers Hemophilia Drugs Manufacturing Sites and Area Served Table 11. Manufacturers Hemophilia Drugs Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Hemophilia Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemophilia Drugs as of 2021) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Hemophilia Drugs Sales by Region (2017-2022) & (K Units) Table 16. Global Hemophilia Drugs Sales Market Share by Region (2017-2022) Table 17. Global Hemophilia Drugs Revenue by Region (2017-2022) & (US$ Million) Table 18. Global Hemophilia Drugs Revenue Market Share by Region (2017-2022) Table 19. North America Hemophilia Drugs Sales by Country (2017-2022) & (K Units) Table 20. North America Hemophilia Drugs Sales Market Share by Country (2017-2022) Table 21. North America Hemophilia Drugs Revenue by Country (2017-2022) & (US$ Million) Table 22. North America Hemophilia Drugs Revenue Market Share by Country (2017-2022) Table 23. Europe Hemophilia Drugs Sales by Country (2017-2022) & (K Units) Table 24. Europe Hemophilia Drugs Sales Market Share by Country (2017-2022) Table 25. Europe Hemophilia Drugs Revenue by Country (2017-2022) & (US$ Million) Table 26. Europe Hemophilia Drugs Revenue Market Share by Country (2017-2022) Table 27. Asia Pacific Hemophilia Drugs Sales by Region (2017-2022) & (K Units) Table 28. Asia Pacific Hemophilia Drugs Sales Market Share by Region (2017-2022) Table 29. Asia Pacific Hemophilia Drugs Revenue by Region (2017-2022) & (US$ Million) Table 30. Asia Pacific Hemophilia Drugs Revenue Market Share by Region (2017-2022) Table 31. Latin America Hemophilia Drugs Sales by Country (2017-2022) & (K Units) Table 32. Latin America Hemophilia Drugs Sales Market Share by Country (2017-2022) Table 33. Latin America Hemophilia Drugs Revenue by Country (2017-2022) & (US$ Million) Table 34. Latin America Hemophilia Drugs Revenue Market Share by Country (2017-2022) Table 35. Middle East and Africa Hemophilia Drugs Sales by Country (2017-2022) & (K Units) Table 36. Middle East and Africa Hemophilia Drugs Sales Market Share by Country (2017-2022) Table 37. Middle East and Africa Hemophilia Drugs Revenue by Country (2017-2022) & (US$ Million) Table 38. Middle East and Africa Hemophilia Drugs Revenue Market Share by Country (2017-2022) Table 39. Global Hemophilia Drugs Sales by Type (2017-2022) & (K Units) Table 40. Global Hemophilia Drugs Sales Market Share by Type (2017-2022) Table 41. Global Hemophilia Drugs Revenue by Type (2017-2022) & (US$ Million) Table 42. Global Hemophilia Drugs Revenue Share by Type (2017-2022) Table 43. Global Hemophilia Drugs Price by Type (2017-2022) & (USD/Unit) Table 44. Global Hemophilia Drugs Sales (K Units) by Application (2017-2022) Table 45. Global Hemophilia Drugs Sales Market Share by Application (2017-2022) Table 46. Global Hemophilia Drugs Revenue by Application (2017-2022) & (US$ Million) Table 47. Global Hemophilia Drugs Revenue Share by Application (2017-2022) Table 48. Global Hemophilia Drugs Price by Application (2017-2022) & (USD/Unit) Table 49. Baxalta Corporation Information Table 50. Baxalta Description and Business Overview Table 51. Baxalta Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 52. Baxalta Hemophilia Drugs Product Table 53. Baxalta Recent Developments/Updates Table 54. Bayer Corporation Information Table 55. Bayer Description and Business Overview Table 56. Bayer Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 57. Bayer Hemophilia Drugs Product Table 58. Bayer Recent Developments/Updates Table 59. CSL Behring Corporation Information Table 60. CSL Behring Description and Business Overview Table 61. CSL Behring Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 62. CSL Behring Hemophilia Drugs Product Table 63. CSL Behring Recent Developments/Updates Table 64. Pfizer Corporation Information Table 65. Pfizer Description and Business Overview Table 66. Pfizer Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 67. Pfizer Hemophilia Drugs Product Table 68. Pfizer Recent Developments/Updates Table 69. Alnylam Pharmaceuticals Corporation Information Table 70. Alnylam Pharmaceuticals Description and Business Overview Table 71. Alnylam Pharmaceuticals Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 72. Alnylam Pharmaceuticals Hemophilia Drugs Product Table 73. Alnylam Pharmaceuticals Recent Developments/Updates Table 74. BioMarin Corporation Information Table 75. BioMarin Description and Business Overview Table 76. BioMarin Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 77. BioMarin Hemophilia Drugs Product Table 78. BioMarin Recent Developments/Updates Table 79. Catalyst Biosciences Corporation Information Table 80. Catalyst Biosciences Description and Business Overview Table 81. Catalyst Biosciences Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 82. Catalyst Biosciences Hemophilia Drugs Product Table 83. Catalyst Biosciences Recent Developments/Updates Table 84. Dimension Therapeutics Corporation Information Table 85. Dimension Therapeutics Description and Business Overview Table 86. Dimension Therapeutics Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 87. Dimension Therapeutics Hemophilia Drugs Product Table 88. Dimension Therapeutics Recent Developments/Updates Table 89. F. Hoffmann-La Roche Corporation Information Table 90. F. Hoffmann-La Roche Description and Business Overview Table 91. F. Hoffmann-La Roche Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 92. F. Hoffmann-La Roche Hemophilia Drugs Product Table 93. F. Hoffmann-La Roche Recent Developments/Updates Table 94. Grifols Corporation Information Table 95. Grifols Description and Business Overview Table 96. Grifols Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 97. Grifols Hemophilia Drugs Product Table 98. Grifols Recent Developments/Updates Table 99. Octapharma Corporation Information Table 100. Octapharma Description and Business Overview Table 101. Octapharma Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 102. Octapharma Hemophilia Drugs Product Table 103. Octapharma Recent Developments/Updates Table 104. Sangamo Biosciences Corporation Information Table 105. Sangamo Biosciences Description and Business Overview Table 106. Sangamo Biosciences Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 107. Sangamo Biosciences Hemophilia Drugs Product Table 108. Sangamo Biosciences Recent Developments/Updates Table 109. Spark Therapeutics Corporation Information Table 110. Spark Therapeutics Description and Business Overview Table 111. Spark Therapeutics Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 112. Spark Therapeutics Hemophilia Drugs Product Table 113. Spark Therapeutics Recent Developments/Updates Table 114. Swedish Orphan Biovitrum Corporation Information Table 115. Swedish Orphan Biovitrum Description and Business Overview Table 116. Swedish Orphan Biovitrum Hemophilia Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 117. Swedish Orphan Biovitrum Hemophilia Drugs Product Table 118. Swedish Orphan Biovitrum Recent Developments/Updates Table 119. Production Base and Market Concentration Rate of Raw Material Table 120. Key Suppliers of Raw Materials Table 121. Hemophilia Drugs Distributors List Table 122. Hemophilia Drugs Customers List Table 123. Hemophilia Drugs Market Trends Table 124. Hemophilia Drugs Market Drivers Table 125. Hemophilia Drugs Market Challenges Table 126. Hemophilia Drugs Market Restraints Table 127. Global Hemophilia Drugs Sales Forecast by Type (2023-2028) & (K Units) Table 128. Global Hemophilia Drugs Sales Market Share Forecast by Type (2023-2028) Table 129. Global Hemophilia Drugs Revenue Forecast by Type (2023-2028) & (US$ Million) Table 130. Global Hemophilia Drugs Revenue Market Share Forecast by Type (2023-2028) Table 131. Global Hemophilia Drugs Sales Forecast by Application (2023-2028) & (K Units) Table 132. Global Hemophilia Drugs Sales Market Share Forecast by Application (2023-2028) Table 133. Global Hemophilia Drugs Revenue Forecast by Application (2023-2028) & (US$ Million) Table 134. Global Hemophilia Drugs Revenue Market Share Forecast by Application (2023-2028) Table 135. Global Hemophilia Drugs Sales Forecast by Region (2023-2028) & (K Units) Table 136. Global Hemophilia Drugs Sales Market Share Forecast by Region (2023-2028) Table 137. Global Hemophilia Drugs Revenue Forecast by Region (2023-2028) & (US$ Million) Table 138. Global Hemophilia Drugs Revenue Market Share Forecast by Region (2023-2028) Table 139. Research Programs/Design for This Report Table 140. Key Data Information from Secondary Sources Table 141. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Hemophilia Drugs Figure 2. Global Hemophilia Drugs Market Share by Type in 2021 & 2028 Figure 3. Hemophilia A Product Picture Figure 4. Inhibitors Product Picture Figure 5. Hemophilia B Product Picture Figure 6. Von Willebrand Disease Product Picture Figure 7. Global Hemophilia Drugs Market Share by Application in 2021 & 2028 Figure 8. Recombinant Therapies Figure 9. Plasma-Derived Therapies Figure 10. Global Hemophilia Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 11. Global Hemophilia Drugs Market Size (2017-2028) & (US$ Million) Figure 12. Global Hemophilia Drugs Sales (2017-2028) & (K Units) Figure 13. Hemophilia Drugs Sales Share by Manufacturers in 2021 Figure 14. Global Hemophilia Drugs Revenue Share by Manufacturers in 2021 Figure 15. The Global 5 and 10 Largest Hemophilia Drugs Players: Market Share by Revenue in 2021 Figure 16. Hemophilia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021 Figure 17. Global Hemophilia Drugs Sales Market Share by Region (2017-2022) Figure 18. Global Hemophilia Drugs Sales Market Share by Region in 2021 Figure 19. Global Hemophilia Drugs Revenue Market Share by Region (2017-2022) Figure 20. Global Hemophilia Drugs Revenue Market Share by Region in 2021 Figure 21. U.S. Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 22. Canada Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 23. Germany Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 24. France Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 25. U.K. Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 26. Italy Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 27. Russia Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 28. China Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 29. Japan Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 30. South Korea Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 31. India Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 32. Australia Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 33. Taiwan Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 34. Indonesia Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 35. Thailand Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 36. Malaysia Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 37. Philippines Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 38. Vietnam Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 39. Mexico Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 40. Brazil Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 41. Argentina Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 42. Turkey Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 43. Saudi Arabia Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 44. U.A.E Hemophilia Drugs Revenue Growth Rate (2017-2022) & (US$ Million) Figure 45. Sales Market Share of Hemophilia Drugs by Type (2017-2022) Figure 46. Manufacturing Cost Structure of Hemophilia Drugs Figure 47. Manufacturing Process Analysis of Hemophilia Drugs Figure 48. Hemophilia Drugs Industrial Chain Analysis Figure 49. Channels of Distribution Figure 50. Distributors Profiles Figure 51. Bottom-up and Top-down Approaches for This Report Figure 52. Data Triangulation Figure 53. Key Executives Interviewed

Baxalta Bayer CSL Behring Pfizer Alnylam Pharmaceuticals BioMarin Catalyst Biosciences Dimension Therapeutics F. Hoffmann-La Roche Grifols Octapharma Sangamo Biosciences Spark Therapeutics Swedish Orphan Biovitrum